Pfizer’s Acquisition Of Angiosyn Brings Complementary Product To Macugen
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase of biotech firm provides Pfizer with another potential ophthalmic agent to complement the age-related macular degeneration therapy Macugen. The deal calls for Pfizer to pay Angiosyn shareholders up to $527 mil., as well as royalties on future product sales.
You may also be interested in...
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
Industry Has Eye For Ophthalmic Uses Of Angiogenesis Inhibitors
New approaches to controlling blood vessel overgrowth, pioneered in oncology, are transforming retinopathy research. Two of the most advanced agents, Pfizer/Eyetech's Macugen and Genentech's Lucentis, block VEGF activity, while Alcon's Phase III candidate Retaane acts later in the angiogenic cascade. Small interfering RNA and gene therapy would work earlier, stopping production of angiogenic factors.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.